Sahsen Ventures
VC Fund
Seattle, United States
Sahsen Ventures is a venture capital firm making investments in for-profit and nonprofit organizations with an emphasis on technology and biotechnology. It was established in 2016 and is based in Seattle, Washington.
- Total investments:
- 87
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Sahsen Ventures invests in
Stages Sahsen Ventures invests in
Countries Sahsen Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Seed
- $1.2M–$25M
- Series A
- $13M–$81M
Investment Focus
Industry
- Biotechnology 41 (47%)
- Health Care 26 (30%)
- Non Profit 19 (22%)
- Medical 13 (15%)
- Pharmaceutical 12 (14%)
Stage
- Funding Round 46 (53%)
- Seed 12 (14%)
- Series A 12 (14%)
- Series C 5 (6%)
- Series B 3 (3%)
Country
- United States 70 (80%)
- China 1 (1%)
- Ghana 1 (1%)
- Canada 1 (1%)
- Cayman Islands 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Bryan White
Co-Founder
|
Co-Founder | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
ZymeCO
|
ZymeCO is a bio-manufacturing company that develops enzyme-based biological products designed for sustainable agriculture and turf management. The company utilizes a bio-process that transforms organic matter to build soil health, accelerate residue decomposition, and boost plant growth. | $4M / Series A / Jul 01, 2026 | |
Synthesize Bio
|
Deep biomedical data is the key to unlocking discoveries and creating therapies. Synthesize Bio uses AI to reduce data collection and analysis from months to minutes for a fraction of the cost in time, personnel, and materials. | $10M / Seed / Sep 16, 2025 | |
Archon Biosciences
|
Archon is a biotechnology firm that creates computationally engineered proteins to unleash potent therapeutic targets beyond the grasp of current methods and improve disease management. | $20M / Seed / Oct 30, 2024 | |
Outpace Bio
|
Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety. It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need. | $144M / Series B / Aug 01, 2024 | |
Insamo
|
Insamo offers the discovery of membrane-permeable & orally available cyclic-peptides which lies in its automated process of designing, synthesizing, and testing at an unprecedented scale. | $12M / Seed / Feb 21, 2024 | |
Parse Biosciences
|
Parse Bio is a biotechnology startup company developing single-cell sequencing kit solutions for researchers.By using combinatorial cDNA barcoding within cells themselves, Parse Biosciences’s technology allows researchers to eliminate the need for complex and expensive microfluidic instruments. Additionally, the company’s technology enablessamples to be fixed, frozen, and stored, allowing researchers to separate out the sample extraction from downstream library preparation steps. This capability empowers researchers to run fixed samples collected on different dates together in a single experiment, providing greater control over sample handling and reducing handling errors. Split Biosciences rebranded as Parse Biosciences in 2020.The Seattle, Washington-based biotech company was established in 2018 by Alex Rosenberg, Charlie Roco, and Georg Friedrich Seelig. | $50M / Series C / Dec 14, 2023 | |
|
Outpace Bio
|
Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety. It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need. | $25M / Series A / Mar 23, 2023 | |
Monod Bio
|
Monod Bio is a life sciences company developing biosensors for protein and other analyte detection. Its biosensor platform combines binding, transduction, and amplification to detect a range of target molecules. It utilizes recent advances in computational protein engineering to create highly modular bio-sensing nano switches that stimulate rapid,sensitive, and inexpensive analytical assays.Monod Bio was founded in 2021 and is headquartered in Seattle, Washington. | $25M / Seed / Aug 15, 2022 | |
Terray Therapeutics
|
Terray Therapeutics is a biotechnology company that integrates experimentation and computation to enhance small molecule drug discovery. The platform generates extensive, precise data through a rapid design-make-test-analyze cycle, allowing for efficient exploration of chemical space. By focusing on both wet lab science and AI, the companyaddresses complex therapeutic challenges across various targets. | $60M / Series A / Feb 15, 2022 | |
HilleVax
|
HilleVax is a biopharmaceutical company that focuses on the development and commercialization of novel vaccines. HilleVax was founded in 2021 and was headquartered in Boston, Massachusetts. | $135M / Venture - Series Unknown / Sep 08, 2021 | |
| See all 87 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Featured in Investor Lists
Recommended lists
FAQ
What does Sahsen Ventures invest in?
Sahsen Ventures invests primarily in Biotechnology, Health Care and Non Profit startups, most often at Funding Round and Seed stage. Most of the 87 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Sahsen Ventures's check size?
Sahsen Ventures typically joins rounds of $1.2M–$25M at Seed and $13M–$81M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Sahsen Ventures participates in.
How do I contact Sahsen Ventures?
Public channels for Sahsen Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Sahsen Ventures?
The team at Sahsen Ventures includes Bryan White (Co-Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
